JP2024511995A5 - - Google Patents
Info
- Publication number
- JP2024511995A5 JP2024511995A5 JP2023557284A JP2023557284A JP2024511995A5 JP 2024511995 A5 JP2024511995 A5 JP 2024511995A5 JP 2023557284 A JP2023557284 A JP 2023557284A JP 2023557284 A JP2023557284 A JP 2023557284A JP 2024511995 A5 JP2024511995 A5 JP 2024511995A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162691P | 2021-03-18 | 2021-03-18 | |
| US63/162,691 | 2021-03-18 | ||
| PCT/US2022/020878 WO2022198001A1 (en) | 2021-03-18 | 2022-03-18 | Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024511995A JP2024511995A (ja) | 2024-03-18 |
| JPWO2022198001A5 JPWO2022198001A5 (https=) | 2025-06-23 |
| JP2024511995A5 true JP2024511995A5 (https=) | 2025-06-23 |
Family
ID=83320877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557284A Pending JP2024511995A (ja) | 2021-03-18 | 2022-03-18 | がん治療における第一選択療法としてのｓＥｐｈＢ４－ＨＳＡ融合タンパク質の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240156908A1 (https=) |
| EP (1) | EP4308149A4 (https=) |
| JP (1) | JP2024511995A (https=) |
| KR (1) | KR20230173108A (https=) |
| CN (1) | CN117120074A (https=) |
| AU (1) | AU2022239581A1 (https=) |
| CA (1) | CA3211742A1 (https=) |
| WO (1) | WO2022198001A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274305B1 (en) * | 1996-12-19 | 2001-08-14 | Tufts University | Inhibiting proliferation of cancer cells |
| EP3368551B1 (en) * | 2015-10-27 | 2023-07-12 | The University Of Queensland | A modified epha4 polypeptide |
| CA3139416A1 (en) * | 2019-02-13 | 2020-08-20 | Vasgene Therapeutics Inc | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
| WO2020190977A1 (en) * | 2019-03-17 | 2020-09-24 | Vasgene Therapeutics Inc | Treatment of cancers using sephb4-hsa fusion proteins |
-
2022
- 2022-03-18 CA CA3211742A patent/CA3211742A1/en active Pending
- 2022-03-18 EP EP22772256.8A patent/EP4308149A4/en active Pending
- 2022-03-18 US US18/282,538 patent/US20240156908A1/en active Pending
- 2022-03-18 KR KR1020237035777A patent/KR20230173108A/ko active Pending
- 2022-03-18 AU AU2022239581A patent/AU2022239581A1/en active Pending
- 2022-03-18 JP JP2023557284A patent/JP2024511995A/ja active Pending
- 2022-03-18 CN CN202280022432.5A patent/CN117120074A/zh active Pending
- 2022-03-18 WO PCT/US2022/020878 patent/WO2022198001A1/en not_active Ceased